Recent studies have found that SCD1 has the ability to sustain GC malignancy through inhibiting ferroptosis via binding of exo-lncFERO to SCD1 mRNA and recruitment of hnRNPA1, or SQLE/cholesterol/mTOR signaling pathway (Mao et al., 2024; Zhang et al., 2021). This evidence concerns the gene HNRNPA1 and gastric cancer.